扩大艾滋病毒/艾滋病治疗规模：从耐多药结核病中吸取的经验教训。

Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis.

作者信息

Gupta Rajesh, Irwin Alexander, Raviglione Mario C, Kim Jim Yong

机构信息

Office of the Director General, WHO, Geneva, Switzerland.

出版信息

Lancet. 2004 Jan 24;363(9405):320-4. doi: 10.1016/S0140-6736(03)15394-9.

DOI:10.1016/S0140-6736(03)15394-9

PMID:14751708

Abstract

The UN has launched an initiative to place 3 million people in developing countries on antiretroviral AIDS treatment by end 2005 (the 3 by 5 target). Lessons for HIV/AIDS treatment scale-up emerge from recent experience with multidrug-resistant tuberculosis. Expansion of treatment for multidrug-resistant tuberculosis through the multipartner mechanism known as the Green Light Committee (GLC) has enabled gains in areas relevant to 3 by 5, including policy development, drug procurement, rational use of drugs, and the strengthening of health systems. The successes of the GLC and the obstacles it has encountered provide insights for building sustainable HIV/AIDS treatment programmes.

摘要

联合国发起了一项倡议，目标是到2005年底让发展中国家的300万人接受抗逆转录病毒药物治疗艾滋病（“三五”目标）。耐多药结核病的近期经验为扩大艾滋病毒/艾滋病治疗提供了借鉴。通过名为绿灯委员会（GLC）的多伙伴机制扩大耐多药结核病治疗，已在与“三五”目标相关的领域取得进展，包括政策制定、药品采购、合理用药以及加强卫生系统。绿灯委员会的成功及其遇到的障碍为建立可持续的艾滋病毒/艾滋病治疗方案提供了启示。